Видео ютуба по тегу Toni Choueiri

ASCOGU25: Toni Choueiri, MD, on LITESPARK003 | Dana-Farber Cancer Institute
ASCOGU25: Toni Choueiri, MD, on LITESPARK003 | Dana-Farber Cancer Institute
PMC Impact - Dr. Toni Choueiri
PMC Impact - Dr. Toni Choueiri
Toni's Legendary Top 10 Papers List!
Toni's Legendary Top 10 Papers List!
#KCRS19: Toni Choueiri, M.D.
#KCRS19: Toni Choueiri, M.D.
Toni Choueiri, MD, Dana-Farber Cancer Institute, Medical Oncology
Toni Choueiri, MD, Dana-Farber Cancer Institute, Medical Oncology
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
ASCO25: Toni Choueiri, MD, ARC-20 Study | Dana-Farber Cancer Institute
Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCC
Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non–Clear Cell RCC
Cancer Research, Best of 2010s: Toni Choueiri, MD
Cancer Research, Best of 2010s: Toni Choueiri, MD
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
ASCOGU25: Toni Choueiri MD., on Casdatifan | Dana-Farber Cancer Institute
Dr Toni Choueiri provides an update on kidney cancer management strategies
Dr Toni Choueiri provides an update on kidney cancer management strategies
Dana-Farber Cancer Institute: Toni K. Choueiri, MD (kidney cancer research at ASCO GU21)
Dana-Farber Cancer Institute: Toni K. Choueiri, MD (kidney cancer research at ASCO GU21)
ASCO23: Toni Choueiri, MD | Dana-Farber Cancer Institute
ASCO23: Toni Choueiri, MD | Dana-Farber Cancer Institute
Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC
Dr. Toni Choueiri on Nivolumab and Cabozantinib Becoming First-Line Therapies in RCC
ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute
ESMO22: Toni Choueiri, MD | Dana-Farber Cancer Institute
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
For physicians: VEGF tyrosine kinase inhibitor treatment risks | Dana-Farber Cancer Institute
Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers
Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers
ESMO23: Toni Choueiri, MD LITESPARK-005 | Dana-Farber Cancer Institute
ESMO23: Toni Choueiri, MD LITESPARK-005 | Dana-Farber Cancer Institute
ESMO23: Toni Choueiri, MD LITESPARK-003 | Dana-Farber Cancer Institute
ESMO23: Toni Choueiri, MD LITESPARK-003 | Dana-Farber Cancer Institute
Highlights in Renal Cell Carcinoma - Dr. Toni Choueiri
Highlights in Renal Cell Carcinoma - Dr. Toni Choueiri
Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC
Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC